Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/11/924   
Active ingredient: Lenalidomide
Indication: Treatment of mantle cell lymphoma
Sponsor: Celgene Europe Limited
1 Longwalk Road, Stockley Park, Uxbridge, Middlesex UB11 1DB, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Revlimid on 14/06/2007 with the number EU/1/07/391

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
31/10/2011 Orphan designation EMA/OD/078/11 (2011)7901 of 27/10/2011